ARC Selects HqO to Transform Campus Experience and Supercharge Members’ Productivity and Performance 26-10-2023, 15:00

Io Therapeutics, Inc., presented data from studies of IRX4204, the company’s phase II clinical development stage, highly selective third generation RXR nuclear receptor agonist compound, supporting its potential use for prevention and treatment of normal 10-07-2024, 07:00

The Metals Company Provides Closing Update on its Registered Direct Offering at $2.00 Per Share Plus Class A Warrants 19-10-2023, 19:55